New Regimen for Localized Gastric Cancers Presented at ASCO

Adding the immunotherapy Imfinzi to standard chemotherapy improves outcomes for people with resectable gastric or ...

JUNE 18, 2025

Four Gene Sequence Mutations Correlate With High Gastric Cancer Mortality Rates

Investigators have identified four genes with mutations linked to the development and progression of gastric ...

MAY 16, 2025

EHR-Based Risk Model Shows Potential To Improve Gastric Cancer Screening

A groundbreaking new study supports the potential of electronic health records as a tool for predicting the risk ...

APRIL 16, 2025

Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma

The FDA has granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and ...

MARCH 20, 2025

Tevimbra Approved for Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemo

The FDA has approved tislelizumab-jsgr (Tevimbra, BeiGene), in combination with platinum and fluoropyrimidine-based ...

JANUARY 13, 2025

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...

DECEMBER 30, 2024

Large Analysis Finds No Need for 5-FU Bolus in Some GI Cancer Regimens

Omitting a bolus of 5-FU as part of a FOLFOX, FOLFIRI or FOLFIRINOX regimen in patients with metastatic ...

DECEMBER 6, 2024

Vyloy With Chemotherapy Approved for Gastric or Gastroesophageal Junction Adenocarcinoma

The FDA has approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a claudin 18.2 (CLDN18.2)-directed cytolytic ...

OCTOBER 21, 2024

High-Risk Groups Would Benefit From Gastric Cancer Screening

Although there's not universal screening for gastric cancer in the United States, high-risk groups deserve ...

MAY 17, 2024

New Hereditary Cancer Test Soon to Be Available in U.S.

A new way to screen for colorectal, gastric and pancreatic cancers will be available soon for use in the United ...

MARCH 12, 2024

FDA Approves Keytruda With Chemotherapy for HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

The FDA approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for ...

NOVEMBER 16, 2023

FDA Amends Keytruda’s Gastric Cancer Indication

On Nov. 7, 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab-, ...

NOVEMBER 10, 2023